Cognition Therapeutics, Inc.
Cognition Therapeutics was founded on a unique combination of biological expertise in synaptic function and plasticity, a deep understanding of and focus on the role of toxic soluble proteins, and proprietary CNS-biased chemistry. Supported by dedicated investors as well as Alzheimer’s disease focused entities including the Alzheimer’s Drug Discovery Foundation and the National Institute on Aging of the NIH, Cognition’s founders, Susan Catalano, Ph.D. and Gilbert Rishton, Ph.D. and their team identified CT1812 and brought this molecule into Phase 2 clinical development.
Cognition’s mission is to stop the unrelenting progression of neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease and dementia with Lewy bodies (DLB), and by doing so alter the impact of the societal tsunami of these fatal diseases.
Based on its initial clinical trial in individuals with mild-to-moderate Alzheimer’s disease, CT1812 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). CT1812 is covered by composition of matter patents worldwide.
CT1812 is currently in Phase 2 development for the treatment of mild-to-moderate Alzheimer’s disease. Cognition intends to expand its pipeline to indications beyond Alzheimer’s disease including dry AMD. More information about the company’s programs may be found here.
Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century
Cognition Therapeutics is a member of the Biotechnology Innovation Organization (BIO), which is dedicated to promoting the value of the current and future biopharmaceutical industry. Modern biotechnology may be a young industry, but in just a few decades the entrepreneurs, scientists, researchers and investors working in this field will have established themselves at the forefront of medical innovation. To learn more about how their work may transform the way we treat patients with a wide range of once-devastating diseases, such as Alzheimer’s disease, and what tools, resources and policies will pave the way to these advances, please click here.